Status:
RECRUITING
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
Lead Sponsor:
Yonsei University
Conditions:
Atrial Fibrillation Patients With Intermediate Stroke Risk
Eligibility:
All Genders
19-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOAC) in atrial fibrillation patients with intermediate stroke risk (CHA2DS2-VASc s...
Eligibility Criteria
Inclusion
- Age: 19\~80 years old
- CHA2DS2-VASc score 1 for male or 2 for female among nonvalvular atrial fibrillation patients
- Patients who agree to register for this study
- Patients who can be observed for the progress after treatment
Exclusion
- Severe liver or kidney dysfunction
- Thyroid dysfunction
- Pregnant or breastfeeding women
- Malignant tumors that have not been completely cured
- Severe structural heart disease
- Predicted survival is less than 12 months
- Patients who do not understand the content of the study or disagree with it
Key Trial Info
Start Date :
July 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
1800 Patients enrolled
Trial Details
Trial ID
NCT04437654
Start Date
July 28 2020
End Date
October 1 2028
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance Cardiovascular Hospital Yonsei University
Seoul, South Korea